Psoriatic arthritis Initial PBS authority application Supporting information form (PB105)

You must lodge this form for an adult patient starting initial PBS subsidised treatment with a biological agent. Where the term biological agent appears it refers to adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and ustekinumab only. This form must be completed by a rheumatologist or clinical immunologist with expertise in the management of psoriatic arthritis.


Page last updated: 6 May 2016

This information was printed Thursday 29 September 2016 from It may not include all of the relevant information on this topic. Please consider any relevant site notices at when using this material.